Background
HIV virus persists in a latent but activatable chronic state, predominantly through epigenetic modification of resting CD4+ T-cells and other immune cells such as macrophages. This necessitates lifelong combination antiretroviral therapy (cART) for people living with HIV (PLWH). Trained immunity is a myeloid specific phenomenon where chromatin is relaxed to a less condensed state at select immune gene loci, facilitating rapid and robust transcription from these loci upon exposure to an immune stimulus. We hypothesized that trained immunity could be a viable approach to reactivate HIV from myeloid HIV reservoirs and possibly facilitate reactivation from CD4 T cell reservoirs.
Methods
We used the established innate training stimuli MDP and β-glucan, along with Syk kinase inhibitors, to train the THP89GFP cell line (an experimental monocytic model for latent HIV-1), whole PBMCs of virally suppressed PLWH under ART, and macrophages derived from these PBMCs. We used qPCR and viral outgrowth assays to detect the presence of viral gene expression and viral production. We also performed single cell RNA sequencing and single cell ATAC seq on trained PBMCs of ART suppressed PLWH to study the cross talk between the myeloid and lymphoid cells and its effect on the reactivation of the CD4 T cell HIV genome.
Results
All 3 trained immunity stimuli activated transcription of HIV-1 from THP89GFP cells. Consistent with the increased transcription of viral genes, we observed that multiple regions of the HIV-1 LTR had increased deposition of H3K27Ac in the trained THP89GFP macrophages. A viral outgrowth assay identified four out of 17 PBMC samples with detectable counts of HIV upon training with Syk inhibitors, MDP and β-glucan. Training of whole PBMCs of ART suppressed PLWH enhanced HIV specific viral gene expression. scRNA sequencing showed PBMC training-induced expression of HIV genes from CD4 T cells and hyper activation of T cells in response to PMA activation.
Conclusions
Our studies show that induction of trained immunity is a viable and novel approach to the reactivation of latently infected HIV-1 from both T cell and macrophage reservoirs. Our data also shows beneficial cross talk between trained myeloid cells and T-lymphocytes in PBMC mixtures, resulting in the reactivation of HIV from T cell reservoirs. Collectively our data shows that the trained immunity strategy could be developed as a novel therapeutic approach for the reactivation of latently infected HIV.
Table or Figure
![]()